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SHORT COMMUNICATION
Intracellular metabolites of mercaptopurine in children with lymphoblastic
leukaemia: a possible indicator ofnon-compliance?
L Lennard', J Welch2 and JS Lilleyman2
'University ofSheffield Department ofMedicine andPharmacology, Section ofMolecular Pharmacology andPharmacogenetics,
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Summary As part of a programme assessing the pharmacokinetics oforal thiopurines given for lymphoblastic
leukaemia, we assayed intracellular metabolites of mercaptopurine in children from all over the United
Kingdom who were given a standard dose of the drug. The metabolites we measured, thioguanine nucleotides
and methylmercaptopurines, are products of two competing metabolic pathways and would be expected to
show an inverse correlation. A total of 327 children from 17 centres in the UK were studied. All were on the
same therapeutic schedule of mercaptopurine. All had been on an unattenuated full protocol-directed dose (at
least 75 mgm-2) for a minimum of 7 days before assay. There was a very wide variation in the concentration
of the two metabolites measured; the thioguanine nucleotides ranged from 0 to 1255 pmol per 8 x 108 red cells
(median 289, lower quartile 210, upper quartile 377) and the methylmercaptopurine metabolites ranged from 0
to 46.3 nmol per 8 x 108 red cells (median 5.18, lower quartile 2.31, upper quartile 11.59). The anticipated
negative correlation was not apparent, but the ratio between the two was not randomly distributed. No child
had both metabolite concentrations in the upper quartiles, but in 32 (10%) children the concentration of both
metabolites was in the lower quartile. Of the 32, only one metabolite was detected in four and none at all in
six. The most likely explanation for these findings is that a minority of children with lymphoblastic leukaemia
fail to take oral mercaptopurine either totally or intermittently. The extent of the problem is unknown, but we
suspect it may be clinically important in at least 10% of patients.
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Cytotoxic thioguanine nucleotides formed from mercap-
topurine are important in the continuing (maintenance)
therapy of the common form of childhood lymphoblastic
leukaemia (ALL). Patients who fail to form adequate
amounts appear to be at higher risk of disease relapse
(Lilleyman and Lennard, 1994). The reasons that individuals
vary in their ability to produce these important intracellular
compounds are not all clear, but one is inherited differences
in activity of the enzyme thiopurine methyltransferase
(TPMT). TPMT facilitates the formation of methylmercap-
topurines at the expense of thioguanine nucleotides by a
competing pathway. So very high thiopurine methyltrans-
ferase activity results in the formation of small amounts of
thioguanine nucleotides and vice versa (Lennard et al.,
1990).
An alternative explanation for differences between patients
is failure to comply with prescribed therapy. This possibility
has received scant attention from paediatric onoclogists so
far, but such data as there are all consistently suggest that
the problem is clinically important. The topic has recently
been reviewed by Davies and Lilleyman (1995).
We have now had the opportunity to assay intracellular
metabolites on a large group of children from all over the
United Kingdom and compare the concentration of
methylmercaptopurines with thioguanine nucleotides. We
thought this would allow us to distinguish between those
with low thioguanine nucleotides due to high TPMT activity
from those with low metabolites for other reasons - including
poor compliance. This report describes our preliminary
findings.
Materials and methods
Subjects andstudy design
Clinicians with patients in the UK Medical Research Council
UK ALL trials were invited to forward blood samples for
measurement of mercaptopurine metabolites from children
with all types ofALL receiving continuing chemotherapy. All
were on trials UKALL X (1985-90) (Chessells et al., 1995)
or XI (1990 to date) (Lilleyman and Lennard, 1994).
Blood samples were requested at a time when the mercap-
topurine dose was at a protocol-directed dose of at least
75 mg m2 for at least 7 preceding days, and not within 6
weeks of a red cell transfusion or within 8 weeks of a block
of 'intensive' chemotherapy. A 5 ml aliquot was taken in a
lithium heparin tube at routine venous access immediately
before a monthly vincristine injection.
Continuing (maintenance) chemotherapy on all trials was
similar and consisted of daily oral mercaptopurine and
weekly oral methotrexate at standard doses of 75 mg m2
and 20 mg m2 respectively. The patients were generally in-
structed to take their tablets on an empty stomach at the
same time each day. The children had full blood counts at
least fortnightly to detect cytopenias. Protocol-directed drug
dose reduction was made if neutropenia (neutrophils
<1 x I0 1'-) or thrombocytopenia (platelets<100 x 1091')
occurred, and when the blood counts recovered above
threshold a protocol-directed cycle of dose increments fol-
lowed. All the children also received a monthly dose of
intravenous vincristine and 5 days of oral prednisolone,
irrespective of blood counts. A 5 day block of five-drug
'intensive' therapy given 3 months into continuing treatment
was randomised in UKALL X but received by all in UKALL
XI. In the latter study there was also a randomised 8 week
'third intensification' at weeks 35-43.
Red blood cell concentrations of thioguanine nucleotides
and methylmercaptopurine metabolites were measured as
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1995previously described (Lennard and Singleton, 1992). Correla-
tions were assessed for statistical significance by Spearman's
rank correlation coefficient (rj). Medians were compared by
the Mann-Whitney U-test, and a two-tailed chi-squared test
(with Yates' correction) was used to compare patient charac-
teristics within subgroups of children. When more than one
sample from any patient had been assayed, the values from
the first sample were used for the purpose of the study.
Results
Blood samples were forwarded from 17 UK centres over a
2.5 year period up to June 1994. They were received from
375 children (33 on UKALL X, 342 on UKALL XI, 138
girls and 237 boys, age 1-15 years, median 5 years). A total
of 327 met the entry requirements for the study, of whom
115 were girls and 212 were boys (age 1-15 years, median 5
years). Of the 48 exclusions, seven samples could not be
processed (lysed or clotted cells), four had no dose recorded
and 34 were sampled at a lower than the standard dose
(19-64mgm-2, median 50 mgm-2). Three children were
described as 'very sensitive' to mercaptopurine, i.e. unable to
tolerate the standard dose. Two of these proved to have
TPMT deficiency and have been reported elsewhere (Lennard
et al., 1993).
For the 327, red blood cell thioguanine nucleotides ranged
from 0 to 1255 pmol per 8 x 108 red cells (median 289, lower
quartile 210, upper quartile 377) and the methylmercap-
topurine metabolites ranged from 0 to 46.3 nmol per 8 x 108
red cells (median 5.18, lower quartile 2.31, upper quartile
11.59). There was no significant difference between median
metabolite concentrations in girls and boys.
For the group as a whole there was no statistically
significant correlation between the thioguanine nucleotide
concentrations and the methylmercaptopurine metabolite
concentrations (r, = 0.007, P>0.5). A plot of the two
metabolites is shown in Figure 1. From this it can be seen
that the relationship between the two was not random and
no child had both metabolite values in the upper quartiles. In
contrast, in 32 children (10%) both metabolite values were
within the lower quartiles, in four of whom only one
metabolite was detectable and in a further six of whom no
metabolites were detectable. If these 32 children were
removed from the analysis there was a significant negative
correlation between the concentration of thioguanine
nucleotides and methylmercaptopurine metabolites
(r, = -0.26, z = 4.46, P<0.001).
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Figure 1 The relationship between red blood cell (RBC)
thioguanine nucleotides (6-TGNs) and methylmercaptopurine
metabolites (MeMPs) for the 327 children studied. One datum
point per child. Thioguanine nucleotides ranged from 0 to
1255 pmol per 8 x 108 red cells (median 289, lower quartile 210,
upper quartile 377) and the methylmercaptopurine metabolites
ranged from 0 to 46.3 nmol per 8 x 108 red cells (median 5.18,
lower quartile 2.31, upper quartile 11.59).
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Age and sex of the 32 'lower quartile' children did not
differ significantly from the rest of the group. Ethnic origin is
not recorded in the UKALL trial data, but it was apparent
that 7 of the 32 had an obviously Asian family name com-
pared with 9 of the 295 remaining children (x2= 18.1,
P<0.001). No data were available on the socioeconomic
status of the 32 families.
Discussion
In patients taking mercaptopurine there is an inverse rela-
tionship between TPMT activity and the intraerythrocyte
concentration of thioguanine nucleotides (Lennard et al.,
1990). This is because the enzyme allows the formation of
methylated metabolites via a competing pathway. It follows
from this that there would be an expected inverse correlation
between the concentrations of methylated metabolites and
thioguanine nucleotides in patients at or near steady state
after 7 days on a standardised dose. The fact that we have
failed to demonstrate such a relationship in a large group of
children appears to be because a proportion of them
exhibited low concentrations of both types of metabolite, or,
in some cases, no detectable metabolites at all. Although the
reason is not known, the most likely explanation is that some
of them failed to comply with their prescribed therapy either
partially or completely. It is impossible to estimate the exact
proportion, but it appears to be 10% or more ofthe children
in the study.
We acknowledge that such a conclusion has to be tentative
and that there are confounding influences in our patients of
which we are ignorant. First, by collecting samples in the
way we did we may have obtained results from a selected
group of children. Some clinicians sent a sample from every
child. Others sent samples on 'problem' children only, though
these were mostly patients unable to tolerate normal doses of
mercaptopurine and who had high metabolite concentrations.
Secondly, mercaptopurine metabolism is obviously affected
by factors other than TPMT or compliance, and no attempt
was made in this study to assess absorption, for example. But
we have yet to encounter a child in our local well-studied
population in whom there are persistent low concentrations
of both methylated mercaptopurines and thioguanine
nucleotides; consequently, malabsorption is unlikely to be a
common problem. Thus, despite these reservations, we feel
we have collected more circumstantial evidence that some
children with ALL fail to take their oral medication
reliably.
While this may superficially be surprising in the face of a
life-threatening disease, the problem is not unique to
leukaemia and has also been recognised in children with
epilepsy and diabetes (Shope, 1981), but reliably identifying
non-compliance is very difficult. Some attempts have been
made in children with cancer. We ourselves looked at a small
group oflocal patients with ALL in whom we measured only
the intracellular thioguanine nucleotides, but did so on more
than one occasion when the patient had been on the same
dose for at least 4 weeks. We took wide fluctuations as
indicative of failure to comply. Of 22 children, four (18%)
showed 2-fold or more variation and two subsequently
admitted failure to take their tablets (Davies et al., 1993).
Other studies of children with malignant disease have used
different techniques to reach broadly similar conclusions,
suggesting non-compliance rates of 20-40% (Smith et al.,
1979; Tebbi et al., 1986; Macdougall et al., 1992), so our
tentative figure of 10% in the present series may be an
underestimate.
Why children might fail to comply is not clear. There are
likely to be several influences. Despite the suggestion that
adolescents and boys may be more delinquent, the age and
sex distribution of our 32 'lower quartile' children was not
clearly different from that in the rest. The only possibly
important difference was that those of the 32 with Asian
family names were strikingly in excess, which might reflect
cultural differences and/or communication difficulties inMercaptopurine metabolites in ALL
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different ethnic groups. It is also possible that socioeconomic
status is relevant, but we have no data on that point.
We are not aware of any data on ethnic differences in
TPMT activities among the Asian population of the Indian
subcontinent, although ethnic differences have been
documented for other racial groups. For example, American
blacks have significantly lower TPMT activities than
American white Caucasians, but the enzyme activity is
similarly polymorphic in both populations (McLeod et al.,
1994). The possibility exists that the distribution of TPMT
activities could differ in Asian populations, and this could
contribute to the lower metabolite concentrations measured
in children with Asian family names. In theory, a very high
TPMT activity could remove most of the drug during intes-
tinal and hepatic first-pass metabolism, and this could result
in a low mercaptopurine availability for the red blood cell
formation of both thioguanine nucleotides and methylmer-
captopurine metabolites, as observed in some of our Asian
children. This speculation is not supported by studies which
have measured TPMT activities, thioguanine nucleotides and
methylmercaptopurines in the same children. Those children
with the highest red blood cell methylmercaptopurine
metabolite concentrations had the highest red blood cell
TPMT activities and vice versa (Lennard et al., 1993).
Whatever the reason, poor compliance is potentially likely
to put patients at higher risk of disease relapse. There is also
another hazard. With the present policy of dose escalation in
the face of normal blood counts there is a danger of severe
myelosuppression if children suddenly start to take an
inflated dose. For this reason we are increasingly inclined to
the view that mercaptopurine metabolites should be
monitored in all children on therapy for ALL, and those with
constitutional high activity of TPMT identified at the outset.
In this way potential non-compliers can be picked out at an
early stage, and the mere act of surveillance may serve to
reduce their number anyway.
In all analyses of clinical ALL trials to date full com-
pliance and adequacy of oral antimetabolite drug effect has
invariably (and naively) been assumed. If current cure rates
for low-risk 'common' ALL are nudging 80% (Rivera et al.,
1993), it is tempting to wonder how much of the remaining
20% could be made up simply by ensuring that patients take
all their tablets. The difficulty of this task should not be
underestimated.
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